uniQure N.V.'s AMT-130 demonstrated an 80% reduction in disease progression for high-dose patients, supported by biomarker data. Huntington's disease affects 41,000 people in the U.S., and the market ...
uniQure recently divested from its Lexington facility to Genezen and freed $25 million while significantly reducing its operating costs. At the same time, AMT-130 has received the FDA’s Breakthrough ...
SmartAsset on MSN
Who Actually Has to Pay the Alternative Minimum Tax (AMT)?
The alternative minimum tax (AMT) was designed to ensure that high-income individuals and trusts pay a minimum level of tax, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results